title: Selective usage of D-type cyclins in lymphoid malignancies.
abstract: Three D-type cyclins, cyclin D1, D2 and D3, belong to the G1 cyclin, which regulates the G1/S transition of the cell cycle, and feature highly homologous amino acid sequences. The cyclin D1 gene was found to be transcriptionally activated in B-lymphoid malignancies with t(11;14), but available information is limited regarding expression of cyclin D2 and D3 in hematopoietic malignancies. We examined the expressions of three D-type cyclins to investigate how these homologous genes are differentially used. Northern blot hybridization with densitometric analyses was performed to examine 64 cell lines and 159 patients with various hematopoietic malignancies. Among lymphoid malignancies, cyclin D1 overexpression was exclusively detected in B cell malignancies accompanied by a genetic event consisting of 11q13 chromosomal translocation, consisting of 13 of 19 (68%) patients with mantle cell lymphoma, two of 11 (18%) with B-chronic lymphocytic leukemia, and one of six (17%) with multiple myeloma. The cyclin D2 expression was significantly higher in T cell malignancies than in B cell malignancies (P = 0.003 for cell lines and P < 0.0001 for patient samples, respectively). In the T cell malignancies, cyclin D2 overexpression was predominantly recognized in those with mature phenotype. Furthermore, cyclin D2 expression was upregulated by phytohemagglutinin (PHA) stimulation of normal T-lymphocytes, suggesting that this simply represents the proliferation status of mature T cells. Although cyclin D3 was ubiquitously expressed, its expression was reduced in lymphoid malignancies with cyclin D1 or D2 overexpression. In myeloid leukemias, although three D-type type cyclins were differentially expressed, no preference for particular D-type cyclins was found. This selective usage of D-type cyclins in lymphoid malignancies suggests an existence of a regulatory mechanism among three D-type cyclins.
authors.affiliation: Laboratory of Chemotherapy, Aichi Cancer Center, Nagoya, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Kuroda
authors.forename: H
authors.initials: H
authors.lastname: Komatsu
authors.forename: Y
authors.initials: Y
authors.lastname: Hosokawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kagami
authors.forename: M
authors.initials: M
authors.lastname: Ogura
authors.forename: S
authors.initials: S
authors.lastname: Nakamura
authors.forename: Y
authors.initials: Y
authors.lastname: Kodera
authors.forename: Y
authors.initials: Y
authors.lastname: Morishima
authors.forename: R
authors.initials: R
authors.lastname: Ueda
authors.forename: M
authors.initials: M
authors.lastname: Seto
mesh_terms: D019070:Cell Lineage; D019938:Cyclin D1 / Q000235:genetics*; D056742:Cyclin D2; D056743:Cyclin D3; D016213:Cyclins / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D019337:Hematologic Neoplasms / Q000235:genetics*; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: C080336:CCND2 protein, human; C534696:CCND3 protein, human; D056742:Cyclin D2; D056743:Cyclin D3; D016213:Cyclins; D019938:Cyclin D1